|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TOMM20 |
Gene summary for TOMM20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TOMM20 | Gene ID | 9804 |
| Gene name | translocase of outer mitochondrial membrane 20 | |
| Gene Alias | MAS20 | |
| Cytomap | 1q42.3 | |
| Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | A0A024R3W2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9804 | TOMM20 | GSM4909286 | Human | Breast | IDC | 1.32e-07 | -1.14e-01 | 0.1081 |
| 9804 | TOMM20 | GSM4909293 | Human | Breast | IDC | 1.23e-39 | 5.97e-01 | 0.1581 |
| 9804 | TOMM20 | GSM4909294 | Human | Breast | IDC | 1.84e-08 | -1.16e-01 | 0.2022 |
| 9804 | TOMM20 | GSM4909296 | Human | Breast | IDC | 2.24e-21 | -4.88e-01 | 0.1524 |
| 9804 | TOMM20 | GSM4909297 | Human | Breast | IDC | 1.64e-34 | -5.60e-01 | 0.1517 |
| 9804 | TOMM20 | GSM4909301 | Human | Breast | IDC | 3.11e-10 | -3.59e-01 | 0.1577 |
| 9804 | TOMM20 | GSM4909308 | Human | Breast | IDC | 8.98e-09 | 3.59e-01 | 0.158 |
| 9804 | TOMM20 | GSM4909309 | Human | Breast | IDC | 1.91e-02 | -2.86e-01 | 0.0483 |
| 9804 | TOMM20 | GSM4909311 | Human | Breast | IDC | 1.21e-52 | -6.24e-01 | 0.1534 |
| 9804 | TOMM20 | GSM4909312 | Human | Breast | IDC | 8.85e-16 | -1.85e-01 | 0.1552 |
| 9804 | TOMM20 | GSM4909313 | Human | Breast | IDC | 5.30e-03 | -1.97e-01 | 0.0391 |
| 9804 | TOMM20 | GSM4909315 | Human | Breast | IDC | 6.30e-22 | 3.23e-01 | 0.21 |
| 9804 | TOMM20 | GSM4909316 | Human | Breast | IDC | 2.87e-02 | 1.91e-02 | 0.21 |
| 9804 | TOMM20 | GSM4909319 | Human | Breast | IDC | 1.99e-61 | -6.77e-01 | 0.1563 |
| 9804 | TOMM20 | GSM4909320 | Human | Breast | IDC | 2.65e-10 | -4.76e-01 | 0.1575 |
| 9804 | TOMM20 | GSM4909321 | Human | Breast | IDC | 5.19e-30 | -4.47e-01 | 0.1559 |
| 9804 | TOMM20 | M2 | Human | Breast | IDC | 2.51e-04 | -8.58e-02 | 0.21 |
| 9804 | TOMM20 | M5 | Human | Breast | IDC | 4.50e-06 | 5.15e-01 | 0.1598 |
| 9804 | TOMM20 | NCCBC11 | Human | Breast | DCIS | 1.23e-04 | 2.00e-01 | 0.1232 |
| 9804 | TOMM20 | NCCBC14 | Human | Breast | DCIS | 1.29e-17 | 1.57e-01 | 0.2021 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001593121 | Oral cavity | EOLP | nucleobase-containing compound transport | 58/2218 | 222/18723 | 3.44e-09 | 2.10e-07 | 58 |
| GO:005065721 | Oral cavity | EOLP | nucleic acid transport | 47/2218 | 163/18723 | 3.53e-09 | 2.12e-07 | 47 |
| GO:005065821 | Oral cavity | EOLP | RNA transport | 47/2218 | 163/18723 | 3.53e-09 | 2.12e-07 | 47 |
| GO:005123622 | Oral cavity | EOLP | establishment of RNA localization | 47/2218 | 166/18723 | 6.73e-09 | 3.48e-07 | 47 |
| GO:001703821 | Oral cavity | EOLP | protein import | 53/2218 | 206/18723 | 2.82e-08 | 1.15e-06 | 53 |
| GO:000660524 | Oral cavity | EOLP | protein targeting | 68/2218 | 314/18723 | 4.95e-07 | 1.34e-05 | 68 |
| GO:007058523 | Oral cavity | EOLP | protein localization to mitochondrion | 31/2218 | 125/18723 | 4.36e-05 | 5.88e-04 | 31 |
| GO:007265523 | Oral cavity | EOLP | establishment of protein localization to mitochondrion | 29/2218 | 120/18723 | 1.24e-04 | 1.37e-03 | 29 |
| GO:000683925 | Oral cavity | EOLP | mitochondrial transport | 46/2218 | 254/18723 | 2.16e-03 | 1.35e-02 | 46 |
| GO:000662623 | Oral cavity | EOLP | protein targeting to mitochondrion | 22/2218 | 100/18723 | 2.83e-03 | 1.68e-02 | 22 |
| GO:000640331 | Oral cavity | NEOLP | RNA localization | 50/2005 | 201/18723 | 8.49e-09 | 4.39e-07 | 50 |
| GO:007259432 | Oral cavity | NEOLP | establishment of protein localization to organelle | 84/2005 | 422/18723 | 1.30e-08 | 6.10e-07 | 84 |
| GO:005065731 | Oral cavity | NEOLP | nucleic acid transport | 40/2005 | 163/18723 | 3.74e-07 | 1.15e-05 | 40 |
| GO:005065831 | Oral cavity | NEOLP | RNA transport | 40/2005 | 163/18723 | 3.74e-07 | 1.15e-05 | 40 |
| GO:005123631 | Oral cavity | NEOLP | establishment of RNA localization | 40/2005 | 166/18723 | 6.24e-07 | 1.82e-05 | 40 |
| GO:001593131 | Oral cavity | NEOLP | nucleobase-containing compound transport | 48/2005 | 222/18723 | 1.51e-06 | 3.77e-05 | 48 |
| GO:001703831 | Oral cavity | NEOLP | protein import | 42/2005 | 206/18723 | 2.98e-05 | 4.54e-04 | 42 |
| GO:000110122 | Oral cavity | NEOLP | response to acid chemical | 30/2005 | 135/18723 | 7.75e-05 | 9.93e-04 | 30 |
| GO:004320021 | Oral cavity | NEOLP | response to amino acid | 24/2005 | 116/18723 | 1.14e-03 | 8.51e-03 | 24 |
| GO:007058532 | Oral cavity | NEOLP | protein localization to mitochondrion | 23/2005 | 125/18723 | 6.70e-03 | 3.42e-02 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TOMM20 | SNV | Missense_Mutation | novel | c.102N>A | p.Phe34Leu | p.F34L | Q15388 | protein_coding | tolerated(0.06) | benign(0.086) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TOMM20 | SNV | Missense_Mutation | novel | c.299N>T | p.Cys100Phe | p.C100F | Q15388 | protein_coding | deleterious(0.01) | possibly_damaging(0.646) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TOMM20 | SNV | Missense_Mutation | novel | c.86N>A | p.Arg29Gln | p.R29Q | Q15388 | protein_coding | tolerated(0.08) | benign(0.148) | TCGA-D6-A6EN-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| TOMM20 | SNV | Missense_Mutation | c.28N>A | p.Ala10Thr | p.A10T | Q15388 | protein_coding | deleterious(0.03) | possibly_damaging(0.836) | TCGA-D7-A4YY-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |